Propanc Biopharma Seeks Orphan Drug Status for PRP, Its Lead Product for Ovarian Cancer Treatment

Propanc Biopharma Seeks Orphan Drug Status for PRP, Its Lead Product for Ovarian Cancer Treatment
Propanc Biopharma has submitted an orphan drug designation request to the U.S. Food and Drug Administration (FDA) for PRP, its lead product for treatment of ovarian cancer. PRP is an intravenous therapy composed by two pancreatic proenzymes – trypsinogen and chymotrypsinogen. "Obtaining orphan drug designation from the FDA for our PRP therapy for ovarian cancer is a significant regulatory milestone that we are looking forward to, and will be a positive step forward in Propanc Biopharma's ongoing efforts to develop effective treatments for metastatic cancer," James Nathanielsz, Propanc Biopharma's CEO, said in a press release. Previous preclinical studies testing PRP’s effects in several cancer stem cells and mouse models of ovarian cancer suggested that the potential therapy halted a process where epithelial cells acquire motile and invasive characteristics typical of mesenchymal cells. Scientists believe that this process – known as epithelial-mesenchymal transition – allows cancer cells to leave their primary location and travel into distant locations within the body, increasing their likelihood to generate metastasis. By halting epithelial-mesenchymal transition, PRP could stop tumor progression and metastasis formation in ovarian cancer. Moreover, additional results suggest it also could repress the development of cancer stem cells (CSCs). Some scientists suggest that cancer stem cells help cancer cells to resist current cancer therapies, including chemotherapy. This leads to cancer
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *